BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3495547)

  • 1. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.
    Papapoulos SE; Frolich M; Mudde AH; Harinck HI; vd Berg H; Bijvoet OL
    J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
    Drake S; Massie JD; Postlethwaite AE; Palmieri GM
    Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary gamma-carboxyglutamic acid and serum osteocalcin as bone markers: studies in osteoporosis and Paget's disease.
    Gundberg CM; Lian JB; Gallop PM; Steinberg JJ
    J Clin Endocrinol Metab; 1983 Dec; 57(6):1221-5. PubMed ID: 6605357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
    ThiƩbaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
    Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment.
    Coulton LA; Preston CJ; Couch M; Kanis JA
    Arthritis Rheum; 1988 Sep; 31(9):1142-7. PubMed ID: 3048274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
    Torres R; de la Piedra C; Rapado A
    Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
    Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
    Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteocalcin concentrations in Paget's disease of bone.
    Wilkinson MR; Wagstaffe C; Delbridge L; Wiseman J; Posen S
    Arch Intern Med; 1986 Feb; 146(2):268-71. PubMed ID: 3484940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
    Chakravarty K; Merry P; Scott DG
    J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
    Vega E; Gonzalez D; Ghiringhelli G; Mautalen C
    J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
    Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of remission of Paget's disease of bone.
    Patel S; Stone MD; Coupland C; Hosking DJ
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.
    Castro-Errecaborde N; de la Piedra C; Rapado A; Alvarez-Arroyo MV; Torres R; Traba ML
    J Clin Endocrinol Metab; 1991 Feb; 72(2):462-6. PubMed ID: 1991815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone.
    Delmas PD; Demiaux B; Malaval L; Chapuy MC; Meunier PJ
    Calcif Tissue Int; 1986 Jan; 38(1):60-1. PubMed ID: 3079654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paget's disease of bone treated in five days with AHPrBP (APD) per Os.
    ThiƩbaud D; Jaeger P; Burckhardt P
    J Bone Miner Res; 1987 Feb; 2(1):45-52. PubMed ID: 3455156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Paget's bone disease with the bisphosphonate APD.
    Mautalen CA
    Henry Ford Hosp Med J; 1983; 31(4):244-8. PubMed ID: 6425243
    [No Abstract]   [Full Text] [Related]  

  • 17. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
    Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA
    J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
    Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
    J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
    Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
    Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.